Pipelines
ET-01
We are currently building a GMP manufacturing facility in Guangzhou, China, and expect to advance ET-01 to clinic in 2019.
ET-02
ET-02 is a CRISPR-based gene-editing therapy to produce Universal Chimeric Antigen Receptor T cell Therapy (U-CAR-T). One of the most exciting treatment breakthroughs in recent years, autologous CAR-T therapies have been approved to treat multiple cancers. By knocking out selected genes involved in immunogenicity, it is possible to produce U-CAR-T from healthy donors as an “off-the-shelf” product to treat cancer patients, potentially resulting in readily availability, more consistent quality and lower cost.
In vivo Therapeutics
We are developing novel gene-editing technology-based therapies to treat selected diseases. To that end, we have also been developing in vivo drug delivery platforms, including virus-based systems and lipid nanoparticles.
